Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of Mobocertinib in Healthy Male Subjects
NCT03811834Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mobocertinib in non-small cell lung cancer (NSCLC), sponsored by Millennium Pharmaceuticals. Primary endpoints: Percent Absolute Oral Bioavailability (%F) for Mobocertinib, Percentage of Total Radioactivity Recovered in Urine and 10 more. Started Jan 2019; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03811834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811834.